Doctors and researchers will be able to easily identify different types of tuberculosis (TB) thanks to a new genetic barcode devised by scientists from the School.

The BCG vaccine has been found to be more effective against the most common form of tuberculosis than previously thought, according to a new study in Clinical Infectious Diseases.

Early results from a clinical drug trial of a new four-month treatment for tuberculosis (TB) indicate that it is well tolerated, but overall could not be considered as an alternative to current six-month standard treatment. The study – one of the first in 35 years – was presented at the 44^th Union World Conference on Lung Health in Paris on 3 November by researchers from the London School of Hygiene & Tropical Medicine on behalf of the Gatifloxacin for TB team.